quantisnow
FeedTopReportsPricing
⌘K
Live feed
07:55:37·58d
ANALYSTRating
Praxis Precision Medicines Inc. logo

Wolfe Research initiated coverage on Praxis Precision Medicines with a new price target

PRAX· Praxis Precision Medicines Inc.
Health Care
Original source

Companies

  • PRAX
    Praxis Precision Medicines Inc.
    Health Care

Recent analyst ratings

  • Apr 10UpdateRaymond James$815.00
  • Feb 24UpdateWolfe Research$500.00
  • Feb 2UpdateWells Fargo$282.00
  • Dec 15UpdateOppenheimer$750.00
  • Nov 19UpdateBTIG Research$424.00
  • Jun 2UpdateOppenheimer$97.00

Related

  • SEC9d
    Praxis Precision Medicines Inc. filed SEC Form 8-K: Other Events
  • PR9d
    Praxis Precision Medicines Announces FDA Acceptance of New Drug Application for Ulixacaltamide HCl in Patients with Essential Tremor
  • PR10d
    Praxis to Showcase Essential3, the First Positive Phase 3 Program in Essential Tremor, at AAN 2026
  • ANALYST13d
    Raymond James initiated coverage on Praxis Precision Medicines with a new price target
  • SEC17d
    Praxis Precision Medicines Inc. filed SEC Form 8-K: Other Events
  • PR17d
    Praxis Precision Medicines Announces Positive Results from the EMBRAVE Part A Trial of Elsunersen in Patients with SCN2A Early-Onset Developmental and Epileptic Encephalopathy
  • PR21d
    Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  • PR24d
    Praxis Precision Medicines Announces FDA Acceptance and Priority Review of New Drug Application for Relutrigine in Patients with SCN2A and SCN8A DEEs
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022